Standard BioTools Inc. Net Fee Amt
Standard BioTools Inc. (LAB) had Net Fee Amt of $7.21 thousand as of 2026-08-04, per its S-8 filed 2026-08-05.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-05
- 2026-08-04: Net Fee Amt $7.21K.
- 2026-07-20: Net Fee Amt $9.39K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $7.21K S-8 · filed 2026-08-05 |
| 2026-07-20 | $9.39K S-4 · filed 2026-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |